|
Antidepressant Induced Sexual Dysfunction Men
Men as well as women will have a
rather high incidence of sexual dysfunction with
antidepressant usage. Studies show, 70% of men taking an
antidepressant will experience sexual dysfunction.
Sexual dysfunction is
one of the more common reasons men discontinue their
antidepressant, even though the antidepressant was helping
their depression.
Therapeutic treatment for sexual
dysfunction might include other medications or supplements.
The medications used for sexual dysfunction come with their
own unique side effect profile and only further reduce
quality of life and the supplements that have been used in
the past interact with antidepressants and cause adverse
reactions and were ineffective at reducing sexual
dysfunction.
Study Design –
Determine if standardized Saffron
would reduce or eliminate antidepressant induced sexual
dysfunction in men.
Study Length – 4 weeks
Participants
– 38 married men between the age of 18-45.
Antidepressant Usage – All test patients were currently
using an antidepressant for a minimum of 6 weeks, had
responded favorably to the antidepressant and depression had
dropped to be mild or non-existent. Patients did not have
depression at the start of study.
Sexual Dysfunction – Test patients did not
have sexual dysfunction before starting the antidepressant.
Sexual dysfunction began after starting the antidepressant.
Patients
were randomly assigned to 15mg Saffron at 15mg, taken twice
each day, or to a placebo at 15mg, taken twice each day.
Results
Depression remained low for entire
group and did not increase with any patient.
Side effect profile with those taking
placebo or Saffron was identical.
More than 50% of test patients taking
this Saffron had a significant improvement in erectile
function. This result makes the Saffron as effective as
phosphodiesterase inhibitors, without the side effects.
Orgasmic function improved to near a
significant level.
Erectile function improved with the Saffron vs placebo
Satisfaction with intercourse improved with the Saffron vs
placebo
Orgasmic function improved with the Saffron vs placebo
Sexual desire improved with the Saffron vs placebo
Overall satisfaction improved with the Saffron vs placebo
What you would take:
Optimum Solace
Where Available:
Neuro Genetic Solutions
How Much to Take: Take 1 veggie capsule
twice daily. Each capsule contains 15mg of the Saffron.
When to Take: Take 1 capsule in the morning and
the second capsule 5 to 6 hours later.
Take at least 1 hour apart from
medications.
Always check with your prescribing physician before starting
any supplement program.
References
Agha-Hosseini M, Kashani L, Aleyaseen A, Ghoreishi A,
Rahmanpour H, Zarrinara AR, Akhondzadeh S (2008) Crocus
sativus L. (saffron) in the treatment of premenstrual
syndrome: a doubleblind, randomised and placebo-controlled
trial. BJOG 115:515–519
Aizenberg D, Zemishlany Z, Weizman A (1995) Cyproheptadine
treatment of sexual dysfunction induced by serotonin
reuptake inhibitors. Clin Neuropharmacol 18:320–324
Akhondzadeh Basti A, Moshiri E, Noorbala AA, Jamshidi AH,
Abbasi SH, Akhondzadeh S (2007) Comparison of petal of
Crocus sativus L. and fluoxetine in the treatment of
depressed outpatients: a pilot double-blind randomized
trial. Prog Neuropsychopharmacol Biol Psychiatry 31:439–442
Akhondzadeh S, Fallah-Pour H, Afkham K, Jamshidi AH,
Khalighi- Cigaroudi F (2004) Comparison of Crocus sativus L.
and imipramine in the treatment of mild to moderate
depression: a pilot double-blind randomized trial
[ISRCTN45683816]. BMC Complement Altern Med 4:12
Akhondzadeh S, Tahmacebi-Pour N, Noorbala AA, Amini H,
Fallah-Pour H, Jamshidi AH, Khani M (2005) Crocus sativus L.
in the treatment of mild to moderate depression: a
double-blind,
randomized and
placebo-controlled trial. Phytother Res 19:148–151
Akhondzadeh S, Sabet MS, Harirchian MH, Togha M,
Cheraghmakani H, Razeghi S, Hejazi S, Yousefi MH, Alimardani
R, Jamshidi A, Zare F, Moradi A (2010a) Saffron in the
treatment of patients with mild to moderate Alzheimer’s
disease: a 16-week, randomized and placebo-controlled trial.
J Clin Pharm Ther 35:581–588
Akhondzadeh S, Shafiee Sabet M, Harirchian MH, Togha M,
Cheraghmakani H, Razeghi S, Hejazi SS, Yousefi MH,
Alimardani R, Jamshidi A, Rezazadeh SA, Yousefi A, Zare F,
Moradi A, Vossoughi A (2010b) A 22-week, multicenter,
randomized,
double-blind controlled trial of Crocus sativus in the
treatment of mild-to-moderate Alzheimer’s disease.
Psychopharmacology (Berl) 207:637–643
Andersson KE (2011) Mechanisms of penile erection and basis
for pharmacological treatment of erectile dysfunction.
Pharmacol Rev 63:811–859
Atmaca M, Korkmaz S, Topuz M, Mermi O (2011) Mirtazapine
augmentation for selective serotonin reuptake
inhibitor-induced sexual dysfunction: a retrospective
investigation. Psychiatry Investig 8:55–57
Aukst-Margetic B, Margetic B (2005) An open-label series
using loratadine for the treatment of sexual dysfunction
associated with selective serotonin reuptake inhibitors.
Prog Neuropsychopharmacol Biol Psychiatry 29:754–756
Baldwin D, Hutchison J, Donaldson K, Shaw B, Smithers A
(2008) Selective serotonin re-uptake inhibitor
treatment-emergent sexual dysfunction: randomized
double-blind placebo-controlled parallel-group fixed-dose
study of a potential adjuvant compound, VML-670. J
Psychopharmacol 22:55–63
Berger F, Hensel A, Nieber K (2011) Saffron extract and
trans-crocetin inhibit glutamatergic synaptic transmission
in rat cortical brain slices. Neuroscience 180:238–247
Boskabady MH, Ghasemzadeh Rahbardar M, Nemati H,
Esmaeilzadeh M (2010) Inhibitory effect of Crocus sativus
(saffron) on histamine (H1) receptors of guinea pig tracheal
chains. Pharmazie 65:300–305
Cappelleri JC, Rosen RC, Smith MD, Mishra A, Osterloh IH
(1999) Diagnostic evaluation of the erectile function domain
of the International Index of Erectile Function. Urology
54:346–351
D’agostino N, Pizzichini D, Chiusano ML, Giuliano G (2007)
An EST database from saffron stigmas. BMC Plant Biol 7:53
Damis
M, Patel Y, Simpson GM (1999) Sildenafil in the treatment of
SSRI-induced sexual dysfunction: a pilot study. Prim Care
Companion J Clin Psychiatry 1:184–187
Debattista C, Solvason B, Poirier J, Kendrick E, Loraas E
(2005) A placebo-controlled, randomized, double-blind study
of adjunctive bupropion sustained release in the treatment
of SSRI-induced sexual dysfunction. J Clin Psychiatry
66:844–848
Demyttenaere K, Jaspers L (2008) Review: bupropion and
SSRIinduced side effects. J Psychopharmacol 22:792–804
Fava
M, Rankin M (2002) Sexual functioning and SSRIs. J Clin
Psychiatry 63(Suppl 5):13–16, discussion 23–15
Feder
R (1991) Reversal of antidepressant activity of fluoxetine
by cyproheptadine in three patients. J Clin Psychiatry
52:163–164
Furukawa K, Nagao K, Ishii N, Uchiyama T (2003) Responses to
serotonin (5HT) in isolated corpus cavernosum penis of
rabbit. Int J Impot Res 15:267–271
Hensley PL, Nurnberg HG (2002) SSRI sexual dysfunction: a
female perspective. J Sex Marital Ther 28(Suppl 1):143–153
Hollander E, Mccarley A (1992) Yohimbine treatment of sexual
side effects induced by serotonin reuptake blockers. J Clin
Psychiatry 53:207–209
Hosseinzadeh H, Jahanian Z (2010) Effect of Crocus sativus
L. (saffron) stigma and its constituents, crocin and
safranal, on morphine withdrawal syndrome in mice. Phytother
Res 24:726–730
Hosseinzadeh H, Sadeghnia HR (2005) Safranal, a constituent
of Crocus sativus (saffron), attenuated cerebral ischemia
induced oxidative damage in rat hippocampus. J Pharm Pharm
Sci 8:394–399
Hosseinzadeh H, Younesi HM (2002) Antinociceptive and
anti-inflammatory effects of Crocus sativus L. stigma and
petal extracts in mice. BMC Pharmacol 2:7
Hosseinzadeh H, Ziaee T, Sadeghi A (2008) The effect of
saffron,Crocus sativus stigma, extract and its constituents,
safranal and crocin on sexual behaviors in normal male rats.
Phytomedicine 15:491–495
Hosseinzadeh H, Sadeghnia HR, Ghaeni FA, Motamedshariaty VS,
Mohajeri SA (2012) Effects of saffron (Crocus sativus L.)
and its active constituent, crocin, on recognition and
spatial memory after chronic cerebral hypoperfusion in rats.
Phytother Res 26:381–386
Hull
EM, Muschamp JW, Sato S (2004) Dopamine and serotonin:
influences on male sexual behavior. Physiol Behav 83:291–307
Keltner NL, Mcafee KM, Taylor CL (2002) Mechanisms and
treatments of SSRI-induced sexual dysfunction. Perspect
Psychiatr Care 38:111–116
Khori
V, Alizadeh AM, Yazdi H, Rakhshan E, Mirabbasi A, Changizi
S, Mazandarani M,Nayebpour M (2011) Frequency-dependent
electrophysiological remodeling of the AV node by
hydroalcohol extract of Crocus sativus L. (saffron) during
experimental atrial fibrillation: the role of endogenous
nitric oxide. Phytother Res doi:10.1002/ptr.3643
Landen M, Eriksson E, Agren H, Fahlen T (1999) Effect of
buspirone on sexual dysfunction in depressed patients
treated with selective serotonin reuptake inhibitors. J Clin
Psychopharmacol 19:268– 271
Michelson D, Kociban K, Tamura R, Morrison MF (2002)
Mirtazapine, yohimbine or olanzapine augmentation therapy
for serotonin reuptake-associated female sexual dysfunction:
a randomized, placebo controlled trial. J Psychiatr Res
36:147–152
Montejo-Gonzalez AL, Llorca G, Izquierdo JA, Ledesma A,
Bousono M, Calcedo A, Carrasco JL, Ciudad J, Daniel E, De La
Gandara J, Derecho J, Franco M, Gomez MJ, Macias JA, Martin
T, Perez V, Sanchez JM, Sanchez S, Vicens E (1997)
SSRI-induced sexual dysfunction: fluoxetine, paroxetine,
sertraline, and fluvoxamine in a prospective, multicenter,
and descriptive clinical study of 344 patients. J Sex
Marital Ther 23:176–194
Moshiri E, Basti AA, Noorbala AA, Jamshidi AH, Hesameddin
Abbasi S, Akhondzadeh S (2006) Crocus sativus L. (petal) in
the treatment of mild-to-moderate depression: a
double-blind, randomized and placebo-controlled trial.
Phytomedicine 13:607–611
Nemati H, Boskabady MH, Ahmadzadef Vostakolaei H (2008)
Stimulatory effect of Crocus sativus (saffron) on
beta2-adrenoceptors of guinea pig tracheal chains.
Phytomedicine 15:1038–1045
Noorbala AA, Akhondzadeh S, Tahmacebi-Pour N, Jamshidi AH
(2005) Hydro-alcoholic extract of Crocus sativus L. versus
fluoxetine in the treatment of mild to moderate depression:
a doubleblind, randomized pilot trial. J Ethnopharmacol
97:281–284
Nurnberg HG, Hensley PL, Gelenberg AJ, Fava M, Lauriello J,
Paine S (2003) Treatment of antidepressant-associated sexual
dysfunction with sildenafil: a randomized controlled trial.
JAMA 289:56–64 Ozmenler NK, Karlidere T, Bozkurt A, Yetkin
S, Doruk A, Sutcigil L, Cansever A, Uzun O, Ozgen F, Ozsahin
A (2008) Mirtazapine augmentation in depressed patients with
sexual dysfunction due to selective serotonin reuptake
inhibitors. Hum Psychopharmacol 23:321–326
Rosen
RC, Riley A, Wagner G, Osterloh IH, Kirkpatrick J, Mishra A
(1997) The international index of erectile function (IIEF):
a multidimensional scale for assessment of erectile
dysfunction. Urology 49:822–830
Rosen
RC, Allen KR, Ni X, Araujo AB (2011) Minimal clinically
important differences in the erectile function domain of the
International Index of Erectile Function scale. Eur Urol
60:1010–1016
Shamsa A, Hosseinzadeh H, Molaei M, Shakeri MT, Rajabi O
(2009) Evaluation of Crocus sativus L. (saffron) on male
erectile dysfunction: a pilot study. Phytomedicine
16:690–693
Shrivastava RK, Shrivastava S, Overweg N, Schmitt M (1995)
Amantadine in the treatment of sexual dysfunction associated
with selective serotonin reuptake inhibitors. J Clin
Psychopharmacol 15:83–84
Taylor MJ, Rudkin L, Hawton K (2005) Strategies for managing
antidepressant-induced sexual dysfunction: systematic review
of randomised controlled trials. J Affect Disord 88:241–254
Waldinger MD, Olivier B (1998) Selective serotonin reuptake
inhibitor-induced sexual dysfunction: clinical and research
considerations. Int Clin Psychopharmacol 13(Suppl 6):S27–S33
Williams VS, Baldwin DS, Hogue SL, Fehnel SE, Hollis KA,
Edin HM (2006) Estimating the prevalence and impact of
antidepressantinduced sexual dysfunction in 2 European
countries: a crosssectional patient survey. J Clin
Psychiatry 67:204–210
Williams VS, Edin HM, Hogue SL, Fehnel SE, Baldwin DS (2010)
Prevalence and impact of antidepressant-associated sexual
dysfunction in three European countries: replication in a
crosssectional patient survey. J Psychopharmacol 24:489–496
|